Anticorps Recombinant de lapin anti-SLAMF7/CD319

SLAMF7/CD319 Recombinant Antibody for FC

Hôte / Isotype

Lapin / IgG

Réactivité testée

souris

Applications

FC

Conjugaison

Non conjugué

CloneNo.

242629G1

N° de cat : 98342-1-RR

Synonymes

CD319, Leukocyte cell-surface antigen, Novel Ly9, SLAM family member 7, Slamf7



Applications testées

Résultats positifs en cytométriesplénocytes de souris,

Dilution recommandée

ApplicationDilution
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Informations sur le produit

98342-1-RR cible SLAMF7/CD319 dans les applications de FC et montre une réactivité avec des échantillons souris

Réactivité souris
Hôte / Isotype Lapin / IgG
Clonalité Recombinant
Type Anticorps
Immunogène Protéine recombinante
Nom complet SLAM family member 7
Masse moléculaire calculée37 kDa
Numéro d’acquisition GenBankNM_144539.5
Symbole du gène Slamf7
Identification du gène (NCBI) 75345
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par protéine A
Tampon de stockage PBS with 0.09% sodium azide
Conditions de stockageStore at 2 - 8°C. Stable for one year after shipment.

Informations générales

Signaling lymphocyte activation molecule (SLAM) family receptors is a group of type I transmembrane receptors belonging to the immunoglobulin superfamily (PMID: 37251372). The SLAM family contains nine members that contain an extracellular segment comprising two or four Ig-like domains (V-like variable and C2-like constant), a transmembrane region and a cytoplasmic tail (PMID: 29662641). They are involved in various physiological and pathological processes, including the regulation of immunological responses and the route of viral entry. SLAMF7, also known as CS1, CRACC or CD319, is expressed on NK cells, CD8+ T lymphocytes, B lymphocytes, and mature dendritic cells (PMID: 28861320). It exerts both activating and inhibitory effects depending on the expression status of SAP or EAT-2. SLAMF7 is overexpressed in multiple myeloma and makes it a target for immunotherapy (PMID: 28861320).

Protocole

Product Specific Protocols
FC protocol for SLAMF7/CD319 antibody 98342-1-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
{{ptg:RelatedPrimaryAntibodies}}